Intervention not reported
Sulfamethoxazole + trimethoprim (1 RCT, 60 participants) · people with liver cirrhosis
The intervention may leads to lower sulfamethoxazole + trimethoprim (1 RCT, 60 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Sulfamethoxazole + trimethoprim (no direct RCT) · people with liver cirrhosis
It is very uncertain whether the intervention changes sulfamethoxazole + trimethoprim (no direct RCT) (very low certainty).
1 finding from 1 review
HR 2.62 [0.62, 11.91]
Studies not reported
Very low
Intervention not reported
Sulfamethoxazole +trimethoprim (1 RCT, 60 participants) · people with liver cirrhosis
It is very uncertain whether the intervention changes sulfamethoxazole +trimethoprim (1 RCT, 60 participants) (very low certainty).
1 finding from 1 review
HR 0.47 [0.2, 1]
Studies not reported
Very low
Intervention not reported
Methotrexate (1 RCT; 50 participants) · patients with moderate to severe eczema
It is very uncertain whether the intervention changes methotrexate (1 RCT; 50 participants) (very low certainty).
1 finding from 1 review
Continuation of hormonal contraceptive method · Women of reproductive age seeking to avoid pregnancy
It is very uncertain whether intensive counseling changes continuation of hormonal contraceptive method compared with usual family planning care (very low certainty).
1 finding from 1 review
Adherence to method use · Women of reproductive age seeking to avoid pregnancy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Continuation of hormonal contraceptive method · Women of reproductive age seeking to avoid pregnancy
It is very uncertain whether reminders (+/‐ educational information) changes continuation of hormonal contraceptive method compared with usual family planning care (very low certainty).
1 finding from 1 review
Adherence to method use as indicated by missed pills per cycle · Women of reproductive age seeking to avoid pregnancy
1 finding from 1 review
Adherence to method use as indicated by on‐time injections overall · Women of reproductive age seeking to avoid pregnancy
Reminders (+/‐ educational information) showed no clear difference in adherence to method use as indicated by on‐time injections overall compared with usual family planning care (low certainty).
1 finding from 1 review
Intervention not reported
Withdrawal of methylphenidate due to serious adverse events (non‐comparative cohort studies) Measured by: proportion of participants withdrawn from treatment Average study duration (range): 7.9 months (1 month to 37 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review
Intervention not reported
Withdrawal of methylphenidate due to adverse events of unknown severity Measured by: proportion of participants withdrawn from treatment Average study duration (range): 4.6 months (21 days to 36 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review
Intervention not reported
Withdrawal of methylphenidate due to non‐serious adverse events Measured by: proportion of participants withdrawn from treatment Average study duration (range): 5.60 months (0.6 months to 41 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review
Intervention not reported
Withdrawal of methylphenidate for unknown reasons Measure by: proportion of participants withdrawn from treatment Average study duration (range): 6.13 months (1 day to 36 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review
Participants able to reduce corticosteroid or IVIg dose by more than 20% · people with CIDP
Methotrexate showed no clear difference in participants able to reduce corticosteroid or IVIg dose by more than… compared with placebo (moderate certainty).
1 finding from 1 review
Change in disability after 26 or more weeks Overall Neuropathy Limitation Scale. Scale from: 0 to 12. · people with CIDP
1 finding from 1 review
Change in disability after 26 or more weeks Amsterdam Linear Disability Scale. Scale from: 0 to 100. · people with CIDP
1 finding from 1 review
Serious adverse events · people with CIDP
Methotrexate showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events · Patients with acute pouchitis
It is very uncertain whether metronidazole changes adverse events compared with budesonide enema (very low certainty).
1 finding from 1 review
Clinical remission · Patients with acute pouchitis
It is very uncertain whether metronidazole changes clinical remission compared with budesonide enema (very low certainty).
1 finding from 1 review
Clinical improvement · Patients with acute pouchitis
It is very uncertain whether metronidazole changes clinical improvement compared with budesonide enema (very low certainty).
1 finding from 1 review